![]() |
市場調查報告書
商品編碼
2147367
中國超音波設備國產化、採購政策及Mindray主導的訂單:全球最具特色的超音波競爭體系專題報告(2024A–2035E)China Ultrasound Domestic Substitution, Procurement Policy, and the Mindray-Led Order: A Focus Report on the World's Most Distinct Ultrasound Competitive System, 2024A-2035E |
||||||
這份 Marketstrat® 重點報告將中國診斷超音波市場作為平行競爭系統進行分析。報告基於 Marketstrat 的超音波核心模型和 Markintel®調查方法,涵蓋了2024年至2035年的系統、服務和人工智慧收入,並更新至2026年 7月初的最新資料。
我們認為,中國的商業策略其實就是籌資策略。出貨量的成長速度遠超過硬體銷售,而剩餘市場佔有率的歸屬則取決於公共採購規則。Mindray顯然從由此產生的替代浪潮中獲益匪淺。
模型涵蓋五大硬體領域,從高階推車到掌上/POCUS設備,以及服務、核心AI經常性收入和AI價值池橋樑。到2035年,緊湊型攜帶式主機將成為主要收入來源,掌上/POCUS設備將實現最快成長,而高階卡帶則因競標壓力將停滯不前。非硬體收入將低於全球平均。
This Marketstrat® Focus Report examines China's diagnostic ultrasound market as a parallel competitive system. Built on Marketstrat's ultrasound core model and the Markintel® methodology, it covers systems, service and AI revenue from 2024 through 2035, with a dated refresh through early July 2026.
In our view, commercial strategy in China is procurement strategy. Shipments expand much faster than hardware revenue, and public procurement rules decide who captures what remains. Mindray is the clearest beneficiary of the resulting substitution wave.
The model covers five hardware segments, from premium carts to handheld/POCUS, plus service, core AI recurring revenue and an AI value-pool bridge. Compact and portable consoles become the revenue center of gravity by 2035 and handheld/POCUS grows fastest, while value carts stall under tender pressure. Above-hardware revenue stays thinner than the global norm.
The report analyzes a Mindray-led order across four linked layers: domestic OEM scale, local AI and software, component sovereignty, and exports. It tracks domestic gains in public-tender value, profiles Mindray, SonoScape, United Imaging Healthcare and smaller local players, and reviews how GE HealthCare, Philips and other multinationals are localizing or narrowing focus.
Systems and ecosystem layers: Revenue, shipments and installed base by hardware segment, the systems growth bridge and the AI value-pool bridge.
Policy architecture: Procurement, renewal, domestic preference, trade measures and NMPA regulation, with a 2024–2026 timeline.
Market structure views: End-market, clinical application, purchase model and operating model mixes.
Refresh and actions: A dated freshness log, recommendations by participant type and 12–24-month signals.
The report treats China as a strategic theater of its own rather than a regional footnote, ties every baseline to Marketstrat's ultrasound core model, and logs later developments separately so readers see what changed.